


RealRate

PHARMACEUTICAL 2018

## ALPINE IMMUNE SCIENCES INC. Rank 38 of 349







RealRate

PHARMACEUTICAL 2018



## ALPINE IMMUNE SCIENCES INC. Rank 38 of 349

The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 135% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Revenues, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 120%, being 398% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	82,548
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,895
Liabilities, Non-Current	4,039
Other Assets	1,585
Other Compr. Net Income	-59
Other Expenses	-48
Other Liabilities	371
Other Net Income	8,332
Property and Equipment	1,089
Research and Development	10,626
Revenues	542
Selling, General and Administrative Expense	6,079

Output Variable	Value in 1000 USD
Assets	85,222
Liabilities	6,305
Expenses	16,657
Stockholders Equity	78,917
Net Income	-7,783
Comprehensive Net Income	-7,812
Economic Capital Ratio	120%

